AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12526285 — intervention group
Group type: COMPARATOR
Intervention: Finasteride (5 mg) once daily for 24 weeks
Number of subjects: 205
Study 12526285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg) at 4 weeks
Number of subjects: 205
Study 12526285 — intervention group
Group type: COMPARATOR
Intervention: Finasteride (5 mg) at 4 weeks
Number of subjects: 205
Study 12526285 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events for Tamsulosin
Number of subjects: 205
Study 12526285 — intervention group
Group type: COMPARATOR
Intervention: Adverse events for Finasteride
Number of subjects: 205
Study 10609436 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 68
Study 10609436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 7718078 — intervention group
Group type: EXPERIMENTAL
Intervention: Video sign warning plus role model
Number of subjects: 0
Study 7718078 — intervention group
Group type: EXPERIMENTAL
Intervention: Video sign warning plus role model with voice warning
Number of subjects: 0
Study 7718078 — intervention group
Group type: COMPARATOR
Intervention: Video sign warning alone
Number of subjects: 0
Study 7718078 — intervention group
Group type: EXPERIMENTAL
Intervention: Video warning with delay
Number of subjects: 0
Study 7718078 — intervention group
Group type: EXPERIMENTAL
Intervention: Video role model and voice warning
Number of subjects: 0
Study 2248062 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (100 mg)
Number of subjects: 0
Study 2248062 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300 mg)
Number of subjects: 0
Study 2248062 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (25 mg)
Number of subjects: 0
Study 2248062 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (75 mg)
Number of subjects: 0
Study 2248062 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (100 mg)
Number of subjects: 0
Study 2248062 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (200 mg, 3 times daily)
Number of subjects: 0
Study 2248062 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (25 mg, twice daily)
Number of subjects: 0
Study 2248062 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (0.6 g/l)
Number of subjects: 0
Study 7410783 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric day care services
Number of subjects: 0
Study 7410783 — intervention group
Group type: EXPERIMENTAL
Intervention: Homemaker services
Number of subjects: 0
Study 7410783 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined geriatric day care and homemaker services
Number of subjects: 0
Study 7410783 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased use of experimental services
Number of subjects: 0
Study 7410783 — intervention group
Group type: COMPARATOR
Intervention: Factors affecting outcomes
Number of subjects: 0
Study 31490252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate (FC)
Number of subjects: 60
Study 31490252 — intervention group
Group type: COMPARATOR
Intervention: Cryoprecipitate
Number of subjects: 60
Study 30106328 — intervention group
Group type: EXPERIMENTAL
Intervention: Music- and verbally cued motor imagery (MVMI)
Number of subjects: 60
Study 30106328 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-cued motor imagery (MMI)
Number of subjects: 60
Study 30106328 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cued motor imagery (MI)
Number of subjects: 60
Study 30106328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued motor imagery (MVMI, MMI)
Number of subjects: 60
Study 28645259 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga programme (n=25)
Number of subjects: 52
Study 28645259 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (n=27)
Number of subjects: 52
Study 26151607 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus + Reduced Tacrolimus (EVR + Reduced TAC)
Number of subjects: 370
Study 26151607 — intervention group
Group type: COMPARATOR
Intervention: Standard exposure Tacrolimus (TAC Control)
Number of subjects: 370
Study 23183751 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1200 IU), folic acid (0.5 mg), vitamin B12 (0.5 mg), vitamin B6 (50 mg), and calcium carbonate (456 mg) (group A)
Number of subjects: 93
Study 23183751 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1200 IU) and calcium carbonate (group B)
Number of subjects: 93
Study 23183751 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins (group A)
Number of subjects: 93
Study 21721475 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (standard multivitamin formula with phytonutrients); details on dosage and duration not specified.
Number of subjects: 0
Study 21721475 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details not available.
Number of subjects: 0
Study 19781415 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve calcification (AVC)
Number of subjects: 357
Study 17922899 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg Nicotinell lozenge
Number of subjects: 900
Study 12898201 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT PET
Number of subjects: 16
Study 12898201 — intervention group
Group type: COMPARATOR
Intervention: FDG PET
Number of subjects: 16
Study 11023459 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 envelope vaccines
Number of subjects: 0
Study 9182469 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 198
Study 9182469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 1587067 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg midazolam
Number of subjects: 6
Study 1587067 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg ephedrine
Number of subjects: 6
Study 1587067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3886400 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil 30 mg b.i.d.
Number of subjects: 11
Study 3886400 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.075-0.15 mg b.i.d.
Number of subjects: 11
Study 29468978 — intervention group
Group type: EXPERIMENTAL
Intervention: Echium amoenum compound syrup (EACS)
Number of subjects: 50
Study 29468978 — intervention group
Group type: COMPARATOR
Intervention: Citalopram tablet
Number of subjects: 50
Study 29479950 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive strip applied to the eyelids post-rhinoplasty
Number of subjects: 0
Study 27175680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 0.25 μg/kg/h diluted to 100 mL in 0.9% saline
Number of subjects: 40
Study 27175680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 40
Study 27175680 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 20 μg/kg diluted to 100 mL in 0.9% saline
Number of subjects: 40
Study 24837862 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body wrapping (covering both body and head with a polyethylene occlusive bag, face uncovered)
Number of subjects: 100
Study 24837862 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (covering only the body up to the shoulders with a polyethylene occlusive bag)
Number of subjects: 100
Study 24837862 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body wrapping
Number of subjects: 100
Study 24837862 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 100
Study 22575396 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic placement of an expandable stent
Number of subjects: 22
Study 22575396 — intervention group
Group type: COMPARATOR
Intervention: Diverting proximal colostomy
Number of subjects: 22
Study 20233202 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg b.i.d.
Number of subjects: 24
Study 20233202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg t.i.d.
Number of subjects: 24
Study 20233202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18477491 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional regimen (13 cycles with 21 days of treatment + 7 days without hormones)
Number of subjects: 59
Study 18477491 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-cycle regimen (four extended cycles with 84 days of continuous administration of EE/DNG, followed by a hormone-free interval of 7 days)
Number of subjects: 59
Study 15816785 — intervention group
Group type: COMPARATOR
Intervention: mirtazapine 30 mg
Number of subjects: 18
Study 15816785 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg and 20 mg
Number of subjects: 18
Study 15816785 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 12551662 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic IOL (MA60BM, Alcon) via temporal corneal incision (Group A)
Number of subjects: 3831
Study 12551662 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic IOL (MA60BM) via superior sclerocorneal incision (Group B)
Number of subjects: 3831
Study 12551662 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone poly(methyl methacrylate) IOL (SI‐40NB, Allergan) via superior sclerocorneal incision (Group C)
Number of subjects: 3831
Study 12551662 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Groups B and C to Group A
Number of subjects: 3831
Study 10376483 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS:BSSG mixture (active capsules)
Number of subjects: 17
Study 10376483 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 17
Study 8777303 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bd + Clarithromycin 250 mg bd + Tinidazole 500 mg bd
Number of subjects: 90
Study 8777303 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 15 mg bd + Amoxicillin 750 mg bd + Metronidazole 500 mg bd
Number of subjects: 90
Study 1647185 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with 30 mg/m2 cisplatin once a week
Number of subjects: 177
Study 1647185 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with 6 mg/m2 cisplatin daily
Number of subjects: 177
Study 1647185 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone (55 Gy, split course)
Number of subjects: 177
Study 6337497 — intervention group
Group type: EXPERIMENTAL
Intervention: levobunolol 0.3%
Number of subjects: 48
Study 6337497 — intervention group
Group type: EXPERIMENTAL
Intervention: levobunolol 0.6%
Number of subjects: 48
Study 6337497 — intervention group
Group type: EXPERIMENTAL
Intervention: levobunolol 1%
Number of subjects: 48
Study 6337497 — intervention group
Group type: EXPERIMENTAL
Intervention: levobunolol 2%
Number of subjects: 48
Study 6337497 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study 31633158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-Ritonavir (LPV/r)
Number of subjects: 159
Study 31633158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir
Number of subjects: 159
Study 30415751 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit Plus™ (NWFP) interactive video games, 14 training sessions, 50 minutes each, twice a week
Number of subjects: 30
Study 30415751 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit Plus™ (NWFP) interactive video games
Number of subjects: 30
Study 30415751 — intervention group
Group type: COMPARATOR
Intervention: General advice regarding the importance of physical activity (Control Group)
Number of subjects: 30
Study 27118812 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) >3 mg/L
Number of subjects: 184
Study 27118812 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) >10 mg/L
Number of subjects: 184
Study 27118812 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CRP levels
Number of subjects: 184
Study 27118812 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HNE levels
Number of subjects: 184
Study 27118812 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels adjusted for severity of acute illness and pre-existing co-morbidity
Number of subjects: 184
Study 27118812 — intervention group
Group type: EXPERIMENTAL
Intervention: HNE levels adjusted for severity of acute illness and pre-existing co-morbidity
Number of subjects: 184
Study 27118812 — intervention group
Group type: EXPERIMENTAL
Intervention: HCMV seropositivity at ICU discharge
Number of subjects: 184
Study 24557088 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (4 mg)
Number of subjects: 70
Study 24557088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 23251997 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous lidocaine infusion of 2 mg/kg/h
Number of subjects: 50
Study 23251997 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 50
Study 20483149 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli 83972 bacteriuria
Number of subjects: 20
Study 20483149 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 18559876 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HDAC; 3 g/m² every 12 hours on days 1, 3, and 5 or 400 mg/m²/d x 5 days)
Number of subjects: 185
Study 18559876 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cytarabine (LDAC; 100 mg/m²/d x 5 days)
Number of subjects: 185
Study 18559876 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HDAC)
Number of subjects: 185
Study 15777307 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 microg) as adjuvant for lidocaine (40 ml of lidocaine at 10 mg/ml)
Number of subjects: 28
Study 15777307 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (40 ml of lidocaine at 10 mg/ml) with saline
Number of subjects: 28
Study 11953281 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenated water
Number of subjects: 66
Study 11953281 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 66
Study 10082242 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg of CCK4
Number of subjects: 16
Study 10082242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8970867 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C‐aided trabeculectomy
Number of subjects: 52
Study 8970867 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy without mitomycin C (Control)
Number of subjects: 52
Study 2326538 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 50
Study 2326538 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 50
Study 6450393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 0
Study 6450393 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES)
Number of subjects: 0
Study 31996186 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/kg bovine lactoferrin (bLF) in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier
Number of subjects: 500
Study 31996186 — intervention group
Group type: COMPARATOR
Intervention: No bovine lactoferrin (bLF) with daily feeds
Number of subjects: 500
Study 31092224 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (OCV)
Number of subjects: 1041
Study 31092224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1041
Study 28893974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccination (V1, n=138)
Number of subjects: 420
Study 28893974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination (V2, n=144)
Number of subjects: 420
Study 28893974 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n=138)
Number of subjects: 420
Study 26053457 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Safety Indicators (PSIs)
Number of subjects: 444751
Study 26053457 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-Acquired Conditions (HACs)
Number of subjects: 444751
Study 26053457 — intervention group
Group type: COMPARATOR
Intervention: High-volume hospitals
Number of subjects: 444751
Study 26053457 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 444751
Study 23537311 — intervention group
Group type: EXPERIMENTAL
Intervention: URS combined with RIRS
Number of subjects: 94
Study 23537311 — intervention group
Group type: COMPARATOR
Intervention: URS alone
Number of subjects: 94
Study 21436390 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity RT
Number of subjects: 18
Study 21436390 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intensity RT
Number of subjects: 18
Study 21436390 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (CR)
Number of subjects: 18
Study 19095869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal‐Iliohypogastric (IG‐IH) and lower intercostal nerve block with bupivacaine 0.5%
Number of subjects: 42
Study 19095869 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 42
Study 18076528 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 1032
Study 18076528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1032
Study 15184252 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to achieve physician consensus, practice changes, and patient activation
Number of subjects: 2520
Study 15184252 — intervention group
Group type: EXPERIMENTAL
Intervention: HMO membership or insurance coverage for six screening procedures
Number of subjects: 2520
Study 15184252 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic staff recommendations for six screening procedures
Number of subjects: 2520
Study 11434597 — intervention group
Group type: COMPARATOR
Intervention: High-dose interferon alpha (IFN-α) alone (5 MU/TIW followed by 10 MU/TIW for 3 months)
Number of subjects: 304
Study 11434597 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon alpha (IFN-α) with ribavirin (approximately 14 mg/kg/day for 3 months)
Number of subjects: 304
Study 11434597 — intervention group
Group type: COMPARATOR
Intervention: High-dose interferon alpha (IFN-α) alone (group A)
Number of subjects: 304
Study 11434597 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon alpha (IFN-α) with ribavirin (group B)
Number of subjects: 304
Study 11732520 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg) given 3 hours before induction of anaesthesia
Number of subjects: 60
Study 11732520 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg) given 1 hour before induction of anaesthesia
Number of subjects: 60
Study 11732520 — intervention group
Group type: COMPARATOR
Intervention: Control group (nothing with 10 ml water)
Number of subjects: 60
Study 9197945 — intervention group
Group type: EXPERIMENTAL
Intervention: RP 60180 (1.0 mg)
Number of subjects: 20
Study 9197945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (50 mg)
Number of subjects: 20
Study 9197945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1550907 — intervention group
Group type: COMPARATOR
Intervention: 100 mg t.i.d.
Number of subjects: 24
Study 1550907 — intervention group
Group type: COMPARATOR
Intervention: 350 mg b.i.d.
Number of subjects: 24
Study 1550907 — intervention group
Group type: COMPARATOR
Intervention: 350 mg t.i.d.
Number of subjects: 24
Study 1550907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3926229 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with iodine-131 or carbimazole in hyperthyroid patients
Number of subjects: 22
Study 3926229 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine replacement therapy in hypothyroid patients
Number of subjects: 22
Study 3926229 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doses of thyroxine replacement therapy in hypothyroid patients
Number of subjects: 22
Study 3926229 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemical tests of liver function
Number of subjects: 22
Study 29262693 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex version of the ACT matrix app
Number of subjects: 98
Study 29262693 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple version of the ACT matrix app
Number of subjects: 98
Study 29262693 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 98
Study 29741615 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 1376
Study 29741615 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 1376
Study 29741615 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 1376
Study 29741615 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilated RV
Number of subjects: 1376
Study 29741615 — intervention group
Group type: EXPERIMENTAL
Intervention: More than mild tricuspid regurgitation (TR)
Number of subjects: 1376
Study 29741615 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening RV function
Number of subjects: 1376
Study 29741615 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of moderate or severe RV dysfunction from baseline normal RV function
Number of subjects: 1376
Study 27667464 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC)
Number of subjects: 66
Study 27667464 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 66
Study 24797938 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - 3×5 min blood pressure cuff inflation/5 min deflation
Number of subjects: 20
Study 24797938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cuff deflated)
Number of subjects: 20
Study 22569857 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpenetrating very deep sclerectomy (NPVDS) with hyaluronic acid implant
Number of subjects: 68
Study 22569857 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy (TB)
Number of subjects: 68
Study 22569857 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpenetrating very deep sclerectomy (NPVDS)
Number of subjects: 68
Study 20360622 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (267 mg/daily)
Number of subjects: 125